Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme

NCT02997423 is registered in ClinicalTrials.gov with University of Iowa as lead sponsor.

NCT NCT02997423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02997423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme
Lead sponsor
University of Iowa
Phase
Observational
Overall status
Completed
Start date
November 30, 2016
Completion date
November 30, 2022
Enrollment
153 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma